Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Meningitis Vaccine Shows Response | Contract Pharma

What are you searching for?

Sign in

Novartis Meningitis Vaccine Shows Response

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

New Phase III data for Novartis’ Menveo show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Sanofi Pasteur’s Menactra. Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the membrane around the brain and spinal cord, or sepsis, a serious infection of the blood stream. Menveo is an investigational quadrivalent meningococcal conjugate vaccine being developed by Novartis Vaccines.
   
Results of this comparator trial show that adolescents who were immunized with Menveo generated higher levels of antibodies against all four serogroups compared to Menactra. Notably for serogroup Y, among adolescents with low levels of immunity at the time of vaccination, 81% of subjects receiving Menveo generated a protective immune response vs. 54% with Menactra. Serogroup Y causes approximately 39% of meningococcal disease cases in the U.S.
   
Meningococcal disease, a leading cause of bacterial meningitis, is a rare but contagious and potentially life-threatening infection. The US CDC recommends routine immunization with a quadrivalent meningococcal conjugate vaccine for all adolescents 11-18 years of age, college freshmen living in dorms and people in other high risk groups who are two to ten or 19-55 years of age.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters